ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)’s share price fell 0% during mid-day trading on Wednesday . The company traded as low as $0.25 and last traded at $0.26. 2,382,200 shares traded hands during mid-day trading, an increase of 142% from the average session volume of 984,097 shares. The stock had previously closed at $0.26.
A number of research firms have issued reports on CTRV. ValuEngine upgraded shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Maxim Group set a $4.00 price objective on shares of ContraVir Pharmaceuticals and gave the company a “buy” rating in a research report on Monday.
The firm has a market capitalization of $22.95, a PE ratio of -0.56 and a beta of 1.92.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.